Manhattan Research's ePharma Physician® study ranks the top online journals by physician visitation

Manhattan ResearchThe New England Journal of Medicine and American Family Physician rank as top online medical journals among U.S. primary care physicians, according to the just released ePharma Physician® v8.0 study by pharmaceutical and healthcare market research company Manhattan Research. Comparing the top online journals of 2007 to this year's batch, the Annals of Internal Medicine and American Family Physician have been two of the most successful publications in increasing online physician readership.

Reading online journals has been one of the fastest growing professional activities for physicians, growing at a double-digit rate over the past three years. The ePharma Physician® v8.0 survey found that physicians expect to increase their use of the Internet as a source of clinical news and information, making it critical for publications like the American College of Physicians Observer, the Cleveland Clinic, the Journal of General Internal Medicine, and others to maintain engaging online versions of their journals.

Top Online Journals among Physicians in 2008
Ranked by Number of U.S. Primary Care Physician Visitors

1. New England Journal of Medicine

2. American Family Physician

3. Annals of Internal Medicine

4. The Lancet

5. American Academy of Family Physicians

6. Journal of the American Medical Association

7. Family Practice Management

8. Cleveland Clinic

9. ACP (American College of Physicians) Observer

10. Journal of General Internal Medicine

Source: ePharma Physician® v8.0 (2008)

ePharma Physician® v8.0 Webcast
Marketers interested in learning more about the latest digital sales and professional marketing trends are invited to attend a webcast from Manhattan Research on August 26. The session is a must-attend event for healthcare and pharmaceutical marketers looking to effectively reach physician audiences through CRM, tech-enabled sales forces, interactive detailing, Web 2.0, pharmaceutical customer service portals, and other strategies. For qualified business accounts only.

Date & Time: Tuesday, August 26, 2008 at 11am and 3pm, EDT

Register Now: Enroll online at http://manhattanresearch.webex.com

About ePharma Physician® v8.0
ePharma Physician® v8.0 was conducted via online survey methodology in Q2 2008 among 1,681 online practicing U.S. physicians.

For seven consecutive years, the study has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit. In-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters and society sites is available as part of the ePharma Physician® v8.0 advisory service.

ePharma Physician® v8.0 also includes the following specialist segments in the research: Allergy and Immunology, Cardiology (Cardiovascular Surgery and Interventional Cardiology), Dermatology, Emergency Medicine, Endocrinology, Family Medicine/General Practice, Gastroenterology, Infectious Disease or HIV physician, Internal Medicine, Nephrology, Neurology, OB/GYN, Oncology-Hematology & Medical, Ophthalmology, Pediatrics, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery (General and Orthopedic), and Urology.

Key Research Topics Covered

ePharma Physician® v8.0 research reveals insight into the following:

  • Interactive Detailing and Technology-Assisted Detailing
  • Top Online Resources
  • Web 2.0 Technologies
  • Email Use and Interest
  • Pharmaceutical Customer Service Portals
  • Top Product and Corporate Websites

ePharma Physician® v8.0 reveals the relevant market share and physician satisfaction for 300+ leading pharmaceutical product websites. A complete list of available product sites is available at www.manhattanresearch.com/products/Strategic_Advisory/ePP/default.aspx

Other Manhattan Research Products and Services
Manhattan Research conducts annual research studies among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen® Health, Cybercitizen® Health Europe, and ePharma Consumer®. Each study serves a unique purpose and focuses on different aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analysis among more than 80 consumer therapeutic segments and 25 physician specialist segments.

Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory firm for pharmaceutical and healthcare companies. For more information, visit www.manhattanresearch.com.

Most Popular Now

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

Abbott launches new initiative to drive diversity …

Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, ed...

Needle-free COVID-19 vaccine shows promise

A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed...

Cleveland Clinic launches first-of-its kind preven…

Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of ...

Novartis to sell its Roche stake in a bilateral tr…

Novartis has agreed to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. Vas...